Francisco Lozano, head of the IDIBAPS Immune receptors of the innate and adaptive system group, has been appointed the new President of the Catalan Society of Immunology. His appointment was approved by the Members’ General Meeting, held during the Society’s 16th Congress, which took place on 24 and 25 November. Lozano substitutes Pablo Engel, also from IDIBAPS, at the helm of the organisation.
The Catalan Society of Immunology, part of the Academic Foundation for Medical and Health Sciences of Catalonia and the Balearic Islands, has as its mission the bringing together of all university degree- and diploma-holders with an interest or connection with the speciality of immunology. The organisation aims to contribute towards the scientific betterment of its members, as well as to promote the teaching, scientific and technical development of their speciality. Furthermore, the Society has a strong commitment to the communication of immunology, medicine, and science to society.
Lozano’s research focuses on identifying and understanding the function of the molecules that regulate the immunological response in health and in disease. Specifically, he studies the immunomodulating properties of scavenger-type lymphoid receptors in models of infection, autoimmunity, and cancer. Currently, this researcher is also exercising as senior consultant of the Immunology Service at the Hospital Clínic Barcelona and Head Professor of Immunology at the University of Barcelona. Trained at the Hospital Clínic and at the laboratory of the winner of the Nobel Prize in Medicine César Milstein, in Cambridge, Francisco Lozano has published 170 articles and 6 patents, directed 21 doctoral theses and founded 2 spin-offs (ImmunNovative Developments SL and Sepsia Therapeutics).
